Cybin, a clinical-stage neuropsychiatry company developing psychedelic-based therapies, has applauded recent comments made by US FDA Commissioner Dr. Martin Makary relating to the importance of accelerating and prioritizing research on the clinical benefits of psychedelic therapeutics. “It is gratifying that the FDA commissioner shares our belief in the potential therapeutic value of these innovative treatments — a long-held belief that stands at the core of Cybin’s mission,” says Cybin CEO, Doug Drysdale.
